MetaCap

Amarin (AMRN) vs Aquestive Therapeutics (AQST)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Amarin (AMRN) has outperformed Aquestive Therapeutics (AQST) over the past year, losing 35.5% versus a loss of 39.5%. Over five years, AQST leads with a -45.7% price change compared with -85.5% for AMRN. Amarin is the larger company by market cap ($444.4 million vs $434.9 million), about 1.0 times the size.

Amarin converts more of its revenue into profit, with a net margin of -18.2% versus -188.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMRN-35.47%AQST-39.51%
+19%-16%-52%
Nov 21, 20251 yearNov 20, 2026
AMRN-86.45%AQST-42.04%
+24%-36%-95%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMRN versus AQST key metrics
MetricAMRNAQST
Share price$10.57$3.46
Market cap$444.39M$434.88M
1-day change-6.13%-6.61%
YTD return-24.28%-46.44%
1-year return-35.47%-39.51%
5-year return-85.48%-45.68%
Forward P/E10.79—
EPS (TTM)$-0.80$-0.65
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$213.65M$44.55M
Revenue growth (YoY)-6.55%-22.61%
Net income (latest FY)$-38.80M$-83.78M
Gross margin56.57%58.35%
Operating margin-23.48%-159.50%
Net margin-18.16%-188.09%
52-week high$17.31$6.74
52-week low$10.56$2.93
Distance from 52-week high-38.94%-48.63%
Analyst consensusnonestrong_buy
Avg. price target upside+22.99%+169.65%
Average volume79.50K2.41M
Shares outstanding42.04M125.69M
Employees80147
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Amarin is more profitable, keeping -18.2 cents of every revenue dollar as net income versus -188.1 cents for Aquestive Therapeutics.
  • Amarin grew revenue faster in its latest fiscal year (-6.55% vs -22.61%).

About Amarin

AMRN stock →

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees

About Aquestive Therapeutics

AQST stock →

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees

AMRN vs AQST FAQ

Which is bigger, Amarin or Aquestive Therapeutics?

Amarin (AMRN) is larger, with a market capitalization of $444.39M compared with $434.88M for Aquestive Therapeutics (AQST).

Which stock has performed better over the past year, AMRN or AQST?

AMRN returned -35.47% over the past 12 months, compared with -39.51% for AQST (price return, excluding dividends). Past performance does not predict future results.

Are Amarin and Aquestive Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons